Only five mammalian species are known to be venomous, and while a large amount of research has been carried out on reptile venom, mammalian venom has been poorly studied to date. Here we describe the status of current research into the venom of the platypus, a semi-aquatic egg-laying Australian mammal, and discuss our approach to platypus venom transcriptomics. We propose that such construction and analysis of mammalian venom transcriptomes from small samples of venom gland, in tandem with proteomics studies, will allow the identification of the full range of mammalian venom components. Functional studies and pharmacological evaluation of the identified toxins will then lay the foundations for the future development of novel biomedical substances. A large range of useful molecules have already been identified in snake venom, and many of these are currently in use in human medicine. It is therefore hoped that this basic research to identify the constituents of platypus venom will eventually yield novel drugs and new targets for painkillers.
Venomous mammals
The platypus (Ornithorhynchus anatinus) is an Australian monotreme with a plethora of unusual features stemming from the position of the monotremes as the earliest extant offshoot from the mammalian lineage. One of the most interesting traits of the platypus is that the male of the species is venomous. Venom in a mammal is extremely unusual: only four other species of mammal are known to be venomous, and these all fall within the order Insectivora (shrews and hedgehogs) [1] . Despite the fact that venom in a mammal is remarkable, and that it may contain biomedically useful substances, our knowledge of platypus and Insectivore venom is incomplete. Here we review current knowledge of platypus venom and discuss our plans for future work. It is hoped that, through the construction and analysis of venom transcriptomes, we will discover the contents and unravel the evolutionary history of mammalian venom.
Platypus venom and the crural system
The venom apparatus in the platypus is known as a crural system. It consists of a venom gland on the dorsocaudal side of the abdomen, which is connected via a venom duct to the spur on each hind leg [2] (Fig. 1) . Juvenile females possess a remnant spur sheath that is subsequently lost during the first year of life, and spurs develop only in males [2] . The gland is thought to migrate during male development from the inner surface of the thigh to the dorsocaudal surface [3] . At maturity, during the spring breeding season, the venom gland increases to peak size (in parallel with increases in testis size) and venom production increases [3] .
The exact function of the platypus crural system is unclear. A significant number of platypuses are killed by foxes and dogs, but the platypus has few native predators (crocodiles, Tasmanian devils and raptors have been observed preying on platypuses) [2, 4] . This, combined with the fact that the venom gland increases in size during the breeding season, suggests that the crural system may have evolved to have a reproductive rather than defensive function. Whatever the original function of platypus venom was, at present the crural system can be used as an effective defence mechanism against potential predators (for example humans and domestic dogs), and it may also be used as an offensive weapon to assert dominance over other male platypuses during the breeding season [2] .
Envenomation occurs when the platypus wraps both hind legs around the victim, driving the spurs into the flesh, and in humans, assistance is often needed to disengage the attacking platypus, as it is able to support its full weight by its spurs [5] . Up to 4 ml of venom is available to be injected each time [3] . However, in practice, it is difficult to obtain anything close to this amount when collecting venom in the field. We have found that the central channel of the spur of an adult male platypus has a diameter of ∼0.2 mm (Fig. 2) , and when we attempted delivery of aqueous solution through this small aperture, it required many seconds under high pressure to achieve 4 ml. When we have acquired samples that have been collected in the field, volumes of the order of 100 µl have usually been obtained.
Platypus envenomation has been known to kill dogs (in the days when retrievers were used to recover platypuses during hunting) [e.g. [6] ], but the trapping of male animals with healed spur marks suggests that envenomation by their own species is not usually fatal [2] ; in one case it was observed that envenomated male platypuses displayed oedema and temporary paralysis of spurred limbs [3] . It has been proposed that envenomation of other platypuses confers an advantage to dominant males by causing pain and inhibition of locomotion in rivals, in order to leave the dominant male at liberty to mate without having to fight many times.
The contents of platypus venom
Although human fatalities due to platypus envenomation have never been reported, the venom does produce swelling and immediate and excruciating pain, which cannot be relieved through normal first-aid practices [5] , as well as nausea, gastric pain, cold sweats and lymph node swelling [3] . Even morphine is reported to be mostly ineffective as an analgesic [5] . In one of the few cases of platypus envenomation recorded in detail, clinical pathology revealed a high erythrocyte sedimentation rate and low total serum protein and albumin levels. The patient also reported generalised 'whole body' pain, localised pain that persisted for several weeks after envenomation, and he also experienced significant muscle wasting of the affected forearm [5] . The unusual symptoms of platypus envenomation suggest that platypus venom may contain clinically useful and potentially novel substances, but our knowledge of platypus venom is incomplete. The venom is known to consist of at least nineteen different peptide fractions along with non-peptide components [7, 8] . To date, only three types of peptides have been identified and fully sequenced: C-type natriuretic peptides (OvCNPs), defensin-like peptides (OvDLPs), and nerve growth factor (OvNGF), and their exact functions are not yet known [9, 10] . A venom peptide isomerase and hyaluronidase have also been discovered, but their full sequences have not been determined [7] , and the venom is also known to have protease activity [7] .
4.
Proteomic studies of platypus venom
The starting point for the identification of the existing components of platypus venom was with the availability of protein characterisation techniques. The reverse-phase HPLC chromatogram of platypus venom reveals many novel polypeptides ranging in size from 4 to 6 kDa [11] [12] [13] and proteins with sizes above 12 kDa. Four of those mentioned above have been isolated and studied, including the OvDLPs, OvCNPs, OvNGF, and the peptide isomerase.
4.1.
Ornithorhynchus venom defensin-like peptides (OvDLPs/DLPs)
The OvDLPs are four polypeptides of ∼5 kDa, so named because one of these polypeptides, DLP-1, was found in earlier studies to have a three-dimensional fold very similar to that of β-defensin-12 [14, 15] , a member of the β-defensin-fold family of polypeptides. This peptide family is found in a diverse array of organisms such as sea anemones, snakes, and humans [16] . β-defensins are ∼35-50 amino acid residues in length, and are generally characterised by a short helix, followed by a small twisted antiparallel β-sheet. They contain six cysteine residues (pairing in the sequence pattern 1-5, 2-4 and 3-6), which are crucial for maintaining the compact central core [16] .
Studies of OvDLPs at both a gene [10, 17] and protein [e.g. [11, 12] ] level have been carried out. The protein DLP-1 is coded for by OvDLP-C, and the protein DLP-2 (and DLP-4, a post-translationally modified form of DLP-2) is coded for by OvDLP-B. The gene coding for DLP-3 has not been identified, although the amino acid sequence of this peptide is very similar to that of DLP-2. In addition, another OvDLP gene (OvDLP-A) has also been identified.
It is believed that in the β-defensins the global fold is robust, and the biological function is determined by the nature of the 10 helix (red and yellow) and β-strands (cyan) is shown [11] . The figure was constructed using MOLMOL [44] . side chains [12] . Members of the β-defensin-fold family possess diverse biological activities, including antimicrobial, ion-channel inhibiting, myonecrotic, and analgesic activities [16] . However, the OvDLPs have no antimicrobial or ion-channel activity, so their exact function is a mystery [11] . It is hypothesised that since they are the most abundant peptides in the venom, the OvDLPs may contribute to the production of the pain that is characteristic of platypus envenomation [12, 16] .
DLP-1
In DLP-1 (coded for by the OvDLP-C gene [10] ), residues 15-18 and 37-40 form an anti-parallel β-sheet, and residues 10-12 form a short 3 10 helix (Fig. 3) . It is also possible that residues 7-8 and residues 30-31 form a short parallel β-sheet. The short 3 10 helix and the anti-parallel β-sheet are connected by residues 13-14.
The two anti-parallel β-strands are twisted and connected by a large loop encompassing residues 19-36, which contains a series of turns [11] . A well-defined hydrophobic region comprising residues Cys-9, Ile-12, Ile-27, Phe-28, Leu-29, Ala-30 and Cys-39 is present in DLP-1. Side chains of Ile-12, Ile-27 and Ala-30 form the central core, while the side chains of Phe-28 and Leu-29 are oriented away and exposed to the aqueous solvent. DLP-1 has 10 positively charged residues and six negatively charged ones. While the cationic residues are concentrated in three regions of the molecule, the basic residues do not form a cluster [11] .
DLP-2 and DLP-4
The 42 residues of DLP-2 (coded for by the OvDLP-B gene [10] ) have 36% sequence similarity with DLP-1 [11] . The six cysteine residues are spaced in the sequence in a similar manner in both peptides, and the 14-17 and 37-40 amino acid stretches, which incorporate most of the anti-parallel β-strands, are also seen in both DLP-1 and DLP-2 [11] . It can be seen in Fig. 4 that DLP-2 has a short helix formed by residues 9-12 and an anti-parallel β-sheet formed by residues 15-18 and 37-40. Residues 13-14 connect the helix to the first anti-parallel β-strand. The anti-parallel β-sheet is twisted and connected by a large loop, formed by residues [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , that surrounds the second β-strand and has four β-turns [11] . The C-terminus is bent near residue 41 and points towards the first β-strand. The N-terminus has a large region of hydrophobic residues, and the side chains of these residues are oriented towards the surface and exposed to the aqueous solvent. DLP-2 also has two highly charged hydrophilic regions, one encompassing part of the first β-strand and two β-turns and the other at the end of the large loop encompassing one β-turn [12] . DLP-4 has an identical amino acid sequence to and the same molecular mass as DLP-2, and the only apparent difference between the two peptides is that that they elute at different retention times in reverse-phase HPLC. The reason for this was a mystery until recently, when it was shown that DLP-2 has a D-amino acid residue at position 2 of its sequence, thus accounting for the HPLC effect [18] . Fig. 4 shows that both peptides are folded in the same way, as both have the same amino acid sequence.
4.3.
Ornithorhynchus venom C-type natriuretic peptides (OvCNPs)
The OvCNPs have high sequence similarity to the mammalian C-type natriuretic peptides, which are characterised by having two cysteines paired together to form a 17-residue loop. The loop can be either A-, B-or C-type, and this is defined by the nature of the terminal extensions beyond the loop [19] . Fig. 4 -A schematic drawing of DLP-4 (A) and DLP-2 (B); 20 different possible structures are overlain as determined by NMR. The location of α-helix (red and yellow) and β-strands (cyan) is shown [12] . These figures were constructed using MOLMOL [44] .
OvCNPs have 39 amino acid residues and are physiologically active, having been found to relax rat uterine smooth muscle, and promote oedema and mast cell histamine release [7, 20, 21] . They can also form ion channels in lipid bilayer membranes [8] . Like DLP-2/4, OvCNP can exist in two isomeric forms (OvCNPa and OvCNPb) [22] . Both have identical amino acid sequences but have different retention times upon elution from reverse-phase HPLC; OvCNPb has a D-amino acid residue at the second position from the N-terminus [23] . Fig. 5 shows the structures of OvCNPa in aqueous solution and SDS micelles. The linear portion of OvCNPa does not have a hydrophobic core, while the cyclic portion has a distinct hydrophobic region centred on the side chain of Phe-24 [22] . This region is important in maintaining the structure of the cyclic portion and is flanked by the side chains of Leu-26, Leu-28, Leu-37, Cys-23 and Cys-39. The fold at the N-terminal extension in OvCNPa has an extended configuration in aqueous solution compared to its more compact configuration in SDS micelles. Both configurations show a β-turn at residues 25-28, but there are significant structural differences in the cyclic portion of the peptide when it is dissolved in the two solvents. The hydrophobic core is present at the centre of the cyclic portion in aqueous solutions, but is absent in SDS micelles; in SDS micelles the disulphide bond between residues 23 and 39 is more extended than in aqueous solution [22] . These differences are determined by the different orientation or nature of turns within the peptide.
4.4.
Ornithorhynchus nerve growth factor (OvNGF)
The nerve growth factor protein isolated from platypus venom (OvNGF) is 13 kDa in size [12] . Nerve growth factor (NGF) is found in a variety of snake venoms. It is hypothesised that NGF from snake venoms may increase the effects of other venom toxins by stimulating various cells in the victims, thus rendering them more susceptible to the effects of envenomation [12] . In humans, NGF can cause hyperalgesia [24] ; it is noted that hyperalgesia is one of the symptoms associated with platypus envenomation. To date, OvNGF has not been studied in detail. Interestingly, in reverse-phase HPLC, OvNGF is co-eluted with DLP-3. It is thus possible that the protein might act synergistically with DLPs to produce the pain that is typical of platypus envenomation [12] . It is also possible that OvNGF might have a very similar function to snake venom NGF, but this has not yet been investigated.
Peptide isomerase
The fact that DLP-2 and OvCNPb both exist in isomeric forms containing a D-amino acid at the second position is very significant. D-amino-acid-containing peptides are more stable in tissues, less prone to protease degradation [25] [26] [27] , and some D-amino-acid-containing peptides in animals and insects are more potent than their L-form counterparts [28] . For example, dermorphin, a heptapeptide containing D-alanine in the second position, isolated from the skin of the South American tree frog (Phyllomedusa sauvagei), is one thousand times more potent than morphine at inducing analgesia when injected into the brain [29] .
The existence of D-amino-acid-containing peptides in platypus venom suggested the presence of an isomerase that is responsible for the interconversion between the isomeric peptides. In 2005, a platypus venom peptide isomerase (also known as L-to-D-peptide isomerase) of ∼ 50-60 kDa was discovered [18] . It is the first such enzyme to be reported in a mammal and is likely to be physiologically important, because OvDLPs are the most abundant peptides in the venom and OvCNPs have potent physiological activity. The peptide isomerase acts on the second amino acid residue from the N-terminus and operates in both directions of the reaction (L-to D-and D-to L-) [30] . The structure of this enzyme has not yet been solved, but a proposed model of its active site was generated based on its substrates (Fig. 6) . [22] . These figures were constructed using MOLMOL [44] .
Earlier studies have shown that the peptide isomerase is active on two 12-residue peptides (IMFFEMQsrsrs and ImFFEMQsrsrs), which were derived from the 7-residue Nterminal segments of DLP-4 and DLP-2, with a solubilising peptide (srsrs) added to the C-terminus [25] . A more recent study of the substrate specificity used synthetic hexapeptides, with the first three amino acid residues derived from the Nterminus of OvDLPs and OvCNPs, followed by a short solubilising peptide (srs) [30] . The analogues of DLP-4 and DLP-2 (IMFsrs and ImFsrs, respectively) and the synthetic hexapeptides that incorporate L-/D-norleucine and L-/D-phenylalanine as the second amino acid residue were found to be the active substrates [30] . In carrying out peptide isomerase assays, the hexapeptide INleFsrs is the preferred substrate, because its isomerisation is the fastest and the peptide is less prone to degradation compared to the methionine-containing DLP-4 analogue. The hexapeptide analogues of OvCNPa and OvCNPb (LLHsrs and LlHsrs, respectively) do not act as substrates [30] , so the full-length chain appears to be required to make the N-terminus a substrate. It is clear that the peptide isomerase is active on shorter peptides with at least three Nterminal amino acid residues in which the second amino acid residue has a long hydrophobic side chain while the third amino acid residue must be aromatic, either phenylalanine or histidine [30] .
The platypus venom peptide isomerase is inhibited by amastatin, which suggests that histidine residues are present in or near the active site [25, 30] . Preliminary results have shown that two histidine residues are encoded in the central portion of the candidate peptide isomerase gene (unpublished data). A two-base mechanism has been proposed for the isomerisation [30] . In this model, two histidine residues are positioned on the opposite sides of the substrate. One deprotonates one face of the α-carbon of the second amino acid residue and forms a planar intermediate, while the other (in its conjugate acid form) reprotonates the opposite side of the α-carbon and forms the stereo-inverted product (Fig. 7) .
The gene coding for DLP-2/DLP-4 (OvDLP-B), which is acted on by the peptide isomerase, is expressed in platypus tissues including brain, intestine, kidney, lung, spleen and testis [17] , which raises the possibility that the isomerase is also expressed here and that it might be expressed in higher mammals. This idea was confirmed by recent work, which has revealed the existence of the peptide isomerase in platypus tissues other than the venom gland (unpublished data). Fig. 6 -Proposed model of the active site of the peptide isomerase. The first three amino acid residues of (A) DLP-4 (IMF) and (B) DLP-2 (ImF) are modelled; the tripeptides are arranged in the same coordinate system with respect to the benzyl-group of phenylalanine [30] . Models were constructed using RasMol [45] . 
5.

Next steps for mammalian venom research
We know very little about mammalian venom. While a basic search of the Web of Science Database (ISI Web of Knowledge, Thomson Reuters, 11th November 2008) using the search term '"reptile venom" OR "snake venom"' yields 4282 hits, a search of the same database using '"mammalian venom" OR "platypus venom" OR "shrew venom"' yields just 34.
The many biomedically useful compounds that have been obtained from reptile venom suggest that the dearth of mammalian venom studies is not due to a lack of utility of this kind of research. One reason may be that reptile venoms, which cause significant numbers of human fatalities, have received research priorities because of the scope for the development of antivenins and also because they are seen as more toxic than mammalian venom. Another important cause is the very limited quantity of mammalian venom available for study [31] . Snake venom from many different species is available in reasonable quantities from research colonies which produce venom year-round [e.g. [32] ]. Platypus venom, on the other hand, is quite difficult to obtain. It must be milked, which involves a certain amount of risk to the researcher, it is only obtained in small quantities, and only half of adult animals (the males) produce it. Furthermore, it is not possible to obtain many samples from captive individuals. Platypuses have been difficult to breed in captivity [33] , meaning that they are generally left undisturbed during the breeding season [34] in order to maximise the chances of breeding success. To obtain venom samples, it is therefore generally necessary to capture animals in the wild, which is a difficult and time-consuming process.
Insectivore venom is also extremely difficult to sample. Most of the venomous insectivores are very small, and so produce low venom yields [35] ; for example, a single specimen of one Insectivore (Neomys foydens) yields only 200 mg of venom gland tissue, meaning that obtaining enough venom to do a comprehensive protein purification study would probably decimate wild populations [1] , and in addition some species (e. g. Solenodon) are endangered. The animals are also extremely difficult to capture alive and keep in captivity, meaning that repeated venom collections are impossible [1] . In short, purification and then characterisation of the components of platypus and Insectivore venom are extremely difficult to do at a protein level alone, given the small amounts of venom available. For example, it took 1-2 ml of crude venom to identify OvDLP, OvCNP, and OvNGF in platypus venom. Therefore, we suggest, like others before us [1] , that the best (and perhaps only) way for research into the components and action of mammalian venom to progress will be through genomic studies, primarily the identification and characterisation of venom genes from venom transcriptomes.
The platypus venom transcriptome
As a first case study, we are constructing and analysing a platypus venom transcriptome (cDNA library) to identify the subset of genes that are active in venom glands. This means it will be possible to identify all of the platypus venom components from a single venom gland by examining the products of the expressed genes. We have obtained a venom gland from an adult male that was killed during the breeding season by a domestic dog. From this, total RNA was extracted and we have constructed a venom gland cDNA library, which is currently undergoing sequencing on Next-Generation platforms.
Separating venom genes from genes coding for normal cellular processes
Traditionally, EST sequencing projects are treated as largescale annotation projects; for each read (or contiguous sequence [contig]), BLAST (Basic Local Alignment Search Tool) or a similar alignment tool is used to identify known proteins that are similar. A potential hurdle to the identification of the full range of platypus venom genes from a venom gland transcriptome is the need to separate genes whose products have toxin function from genes coding for normal cellular processes. As the platypus is separated from other mammals by a large evolutionary distance (monotremes diverged from the mammalian lineage 166 million years ago [9] ), it is difficult to identify orthologues by simply searching the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/) with the transcriptome read data using BLAST. The fact that many venom genes in other species have been shown to have evolved from genes coding for normal cellular products [36] also means that it is difficult to reject an expressed gene as a venom component just because it has some homology with a gene coding for a protein involved in a 'conventional' cellular process.
The approach taken in several snake venom sequencing projects has been to assemble sequence information into contigs and then to search contigs against the GenBank database, using an E-value cut-off to separate toxin and cellular functioning genes [e.g. [37, 38] ]. It is then possible to classify the toxin genes into functional groups according to the sequences with which they share strong homology. This approach works well because there are a multitude of venomous snake species, and the venom of some of them has been well-studied, though truly novel components may still be missed. This means that there are a large number of snake venom sequences from reasonably close relatives available to search; ToxProt, a database of animal toxins (http://ca.expasy.org/sprot/tox-prot/), contains 1060 reptilian venom sequences at present (11th November 2008). Clearly this is not the case for venomous mammals; the ToxProt database contains only seven mammalian toxin sequences (11th November 2008).
Our approach
The availability of the platypus genome [9] provides us with an additional resource for transcriptomic studies including a predicted gene build and framework for discovering novel venom proteins. To make use of these, we will map platypus venom transcriptome data to the platypus genome and examine overlapping Ensembl gene predictions (http://www.ensembl.org/ Ornithorhynchus_anatinus/Info/Index), and where there are no annotated genes, construct our own gene predictions in the area of each read hit.
To begin with, we are assigning gene ontology terms to as many venom gland transcripts as possible in order to identify putative functions [39] . We have previously shown that all of the platypus venom genes for which we currently have sequence have homologues in reptile venom, and we have suggested that there are specific classes of proteins that are preferentially selected during the evolution of venom proteins [10] . Therefore, we anticipate that many of the newly identified platypus venom genes will also have reptilian venom homologues. We will also be seeking to link toxin gene annotation to these platypus venom transcripts using BLASTs against the ToxProt (http://ca.expasy.org/sprot/toxprot/) and ATDB [40] databases. In this way, we hope to be able to start the preliminary toxin classification to a number of genes that are expressed in the platypus venom gland.
Since platypus and reptile venoms have evolved separately [10] , it is possible that some components of the venom will be completely novel and be unannotated by Ensembl or have no predicted function and have no homologues in ToxProt. These novel platypus venom components may be the most interesting outcomes of the transcriptome project, as they may have functions that have not been observed in any other venoms to date. This also means that they may be the most promising candidates for the development of novel drugs.
At the time of library construction and sequencing only a single venom gland obtained from a male during the breeding season (which was therefore producing large amounts of venom) was available, and no juvenile or out-of-season gland was available. Consequently, it was decided to normalise the cDNA library. This had the advantage of increasing the chances of detecting rare (lowly expressed) venom gland transcripts, and made the sequencing coverage of transcripts more uniform, thereby improving the transcript assembly quality and also providing a resource to improve the annotation of the genome in general. However, it was at the expense of expression abundance information on each gene, which could hold some clue as to the importance of each transcript in venom. In the future, we plan to explore transcript abundance through the use of unnormalised cDNA from contrasting venom-producing and non-venom producing glands using microarrays or RNA-seq. In particular, genes that are differentially expressed between the breeding and non-breeding season venom glands will play critical roles in venom. The seasonal nature of platypus venom makes platypus something of a special case for transcriptomics and affords us the opportunity to use differential expression analysis to find venom genes. More generally, whether to initially normalise cDNA libraries from mammalian venom glands and rely only on homology, or to not normalise and utilise within-tissue abundance information, is an important experimental design decision. Regardless, final validation of putative toxin proteins will require the appropriate in vitro and in vivo assays.
Once putative toxin transcripts have been identified, they can then be synthesised as peptides in vitro or expressed as protein in cells to study their biological effects. It is recognised that some proteins will not be in the correct post-translational conformation and some will be beyond current protein synthesis capabilities due to their size. Nevertheless, we propose that this approach will be very informative toward defining the biological properties of mammalian venom proteins. Proteomics studies will be carried out in tandem with our transcriptome evaluation. By comparing the protein expression profiles of the platypus venom gland obtained during the breeding season and the non-breeding season, we can identify the proteins that are expressed uniquely during the breeding season and collate this data with the differential RNA expression data from transcriptomes. Protein identification can be done by the combined use of two-dimensional gel electrophoresis and mass spectrometry; first to explore the differences in protein expression levels using two-dimensional gel electrophoresis, and then spot identification of proteins by mass spectrometry. This work is currently in progress.
6.3.
The importance of studying platypus and other mammalian venoms
This work on platypus venom will be followed by a similar shrew venom transcriptome project. Identification of the components of both platypus and shrew venoms would provide insight into the mechanisms of the evolution of mammalian venom and the reasons why it is a comparatively rare trait.
The utility of mammalian venom transcriptome projects should also extend to having human benefits. An understanding of mammalian venoms may improve knowledge of intra-and intercellular signalling in mammals. For example, further research into the platypus venom peptide isomerase may lead to its identification in higher animals including humans, where D-amino acids possibly participate in the aetiology of altered-protein-turnover diseases like Alzheimer's and amyloidosis [41] .
Another promising benefit that may come from mammalian venom research is the discovery of novel therapeutic agents. Snake venoms have already been used in many pharmaceutical applications [42] . The identification of mammalian venom components will allow their synthesis and subsequent functional characterisation, and it is anticipated that this will provide another rich source of new molecules for pharmaceutical design. For example, given that D-amino-acidcontaining peptides and proteins are more stable in vivo, medically useful therapeutic peptides with greater stability in vivo may eventuate from platypus venom peptide isomerase research. In fact, despite the dearth of mammalian venom research to date, there is already a patent for the use of soricidin (a shrew venom peptide) as an analgesic, a wrinkle treatment, a mechanism to immobilise muscles to treat neuromuscular diseases, and a treatment for excessive sweating [43] . The unusual symptoms of platypus envenomation suggest that platypus venom contains many unique substances which may also be clinically useful. In particular, we are interested to identify the toxin that causes the extreme pain. It is possible that this could lead to the discovery of new human pain receptors and thus targets for painkillers.
In conclusion, the construction and sequencing of a platypus venom gland cDNA library, used in combination with the recently sequenced platypus genome [9] , promises to be an efficient means of discovering new venom genes. Complementary studies in genomics and proteomics have the potential to substantially increase our knowledge of mammalian venoms. We anticipate that this will allow the identification of the remaining platypus venom components and pave the way for further investigations of mammalian venom in general, functional studies, and the development of novel pharmaceuticals.
